Advertisement

Current Cardiology Reports

, 16:538 | Cite as

Electronic Cigarettes for Smoking Cessation

  • Christopher Bullen
Ischemic Heart Disease (D Mukherjee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Ischemic Heart Disease

Abstract

Electronic cigarettes (e-cigarettes) are novel vaporising devices that, similar to nicotine replacement treatments, deliver nicotine but in lower amounts and less swiftly than tobacco smoking. However, they enjoy far greater popularity than these medications due in part to their behaviour replacement characteristics. Evidence for their efficacy as cessation aids, based on several randomised trials of now obsolete e-cigarettes, suggests a modest effect equivalent to nicotine patch. E-cigarettes are almost certainly far less harmful than tobacco smoking, but the health effects of long-term use are as yet unknown. Dual use is common and almost as harmful as usual smoking unless it leads to quitting. Population effects, such as re-normalising smoking behaviour, are a concern. Clinicians should be knowledgeable about these products. If patients who smoke are unwilling to quit or cannot succeed using evidence-based approaches, e-cigarettes may be an option to be considered after discussing the limitations of current knowledge.

Keywords

Electronic cigarettes E-cigarettes Tobacco Nicotine Smoking Cessation Harm reduction Dependence 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Chris Bullen declares he has received in-kind support from the manufacturer of a smoking cessation medication for giving a guest lecture but has no other conflict of interest.

Human and Animal Rights and Informed Consent

This article contains reference to studies the author conducted with human participants, all who gave informed consent and were conducted with appropriate ethical review. No animal subjects were involved in studies performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharm Econ. 1997;11:538–49.CrossRefGoogle Scholar
  2. 2.
    Fagerstrom K, Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat. 2008;4:353–63.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Stead L, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2011;11:CD000146.Google Scholar
  4. 4.
    Fiore MC, Schroeder SA, Baker TB. Smoke, the chief killer—strategies for targeting combustible tobacco use. N Engl J Med. 2014;370:297–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Adkison SE, O’Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong H-H, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013;44:207–15.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.••
    Abrams DB. Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA. 2014;311:135–6. This article provides an excellent overview of the potential benefits and harms of e-cigarettes at individual and population levels and has provoked a debate suggesting that e-cigarettes may have a role in tobacco control.PubMedCrossRefGoogle Scholar
  7. 7.
    McQueen A, Tower S, Sumner W. Interviews with “vapers”: implications for future research with electronic cigarettes. Nicotine Tob Res. 2011;13:860–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Noel JK, Rees VW, Connolly GN. Electronic cigarettes: a new ‘tobacco’ industry? Tob Control. 2011;20:81.PubMedCrossRefGoogle Scholar
  9. 9.
    Grana RA, Ling PM. “Smoking revolution”: a content analysis of electronic cigarette retail websites. Am J Prev Med. 2014;46:395–403.PubMedCrossRefGoogle Scholar
  10. 10.
    Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: adult use and awareness of the ‘e-cigarette’ in the USA. Tob Control. 2013;22:19–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Tan ASL, Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med. 2014;47:141–9. doi: 10.1016/j.amepre.2014.02.011.PubMedCrossRefGoogle Scholar
  12. 12.
    King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness and ever use of electronic cigarettes among U.S. Adults, 2010–2011. Nicotine Tob Res. 2013;15:1623–7. doi: 10.1093/ntr/ntt013.PubMedCrossRefGoogle Scholar
  13. 13.•
    Zhu SH, Gamst A, Lee M, Cummins S, Yin L, Zoref L. The use and perception of electronic cigarettes and snus among the U.S. population. PLoS One. 2013;8:e79332. doi: 10.1371/journal.pone.0079332. The article provides recent survey data on e-cigarette use drawing on a robust sample of the US population.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Grana RA. Electronic cigarettes: a new nicotine gateway? J Adolesc Health. 2013;52:135–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Corey C, Wang B, Johnson SE, Apelberg B, Husten C, King BA, et al. Cancer-related news from the CDC: electronic cigarette use among middle and high school students. Oncol Times. 2013;35:36.CrossRefGoogle Scholar
  16. 16.
    Zhu S-H, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23:iii3–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Brown CJ, Cheng JM. Electronic cigarettes: product characterisation and design considerations. Tob Control. 2014;23:ii4–10.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Etter J-F. Electronic cigarettes: a survey of users. BMC Public Health. 2010;10:231.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Vickerman KA, Carpenter KM, Altman T, Nash CM, Zbikowski SM. Use of electronic cigarettes among state tobacco cessation quitline callers. Nicotine Tob Res. 2013;15:1787–91. doi: 10.1093/ntr/ntt061.PubMedCrossRefGoogle Scholar
  20. 20.
    Pepper JK, Brewer NT. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. Tob Control. 2013. doi: 10.1136/tobaccocontrol-2013-051122.PubMedCentralGoogle Scholar
  21. 21.
    Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Wullner U, Gundisch D, Herzog H, Minnerop M, Joe A, Warnecke M, et al. Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett. 2008;430:34–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.PubMedGoogle Scholar
  24. 24.
    Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98–103.PubMedCrossRefGoogle Scholar
  25. 25.
    Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19:87–8.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267–70.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang Y, Sumner W, Chen D-R. In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns. Nicotine Tob Res. 2013;15:501–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Etter JF, Bullen C. Saliva cotinine levels in users of electronic cigarettes. Eur Respir J. 2011;38:1219–20.PubMedCrossRefGoogle Scholar
  30. 30.
    Williams M, Talbot P. Variability among electronic cigarettes in the pressure drop, airflow rate, and aerosol production. Nicotine Tob Res. 2011;13:1276–83.PubMedCrossRefGoogle Scholar
  31. 31.
    Schroeder MJ, Hoffman AC. Electronic cigarettes and nicotine clinical pharmacology. Tob Control. 2014;23:ii30–5.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Hua M, Yip H, Talbot P. Mining data on usage of electronic nicotine delivery systems (ENDS) from YouTube videos. Tob Control. 2013;22:103–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Vansickel AR, Weaver MF, Eissenberg T. Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction. 2012;107:1493–500.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274:1353–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Buchhalter AR, Acosta MC, Evans SE, Breland AB, Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction. 2005;100:550–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Brody AL, Mandelkern MA, Costello MR, Abrams AL, Scheibal D, Farahi J, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12:305–16.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Hajek P, McRobbie H, Gillison F. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med. 2007;44:230–4. doi: 10.1016/j.ypmed.2006.10.005.PubMedCrossRefGoogle Scholar
  40. 40.
    Berlin I, Anthenelli RM. Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol. 2001;4:33–42.PubMedCrossRefGoogle Scholar
  41. 41.
    Carpenter CM, Wayne GF, Connolly GN. The role of sensory perception in the development and targeting of tobacco products. Addiction. 2007;102:136–47.PubMedCrossRefGoogle Scholar
  42. 42.
    Wagener TL, Meier E, Hale JJ, Oliver ER, Warner ML, Driskill LM, et al. Pilot investigation of changes in readiness and confidence to quit smoking after e-cigarette experimentation and 1 week of use. Nicotine Tob Res. 2014;16:108–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106:2017–28.PubMedCrossRefGoogle Scholar
  44. 44.
    Grana RA, Popova L, Ling PM. A longitudinal analysis of electronic cigarette use and smoking cessation. JAMA Int Med. 2014;174:813–4.CrossRefGoogle Scholar
  45. 45.
    Caponnetto P, Cibella F, Mancuso S, Campagna D, Arcidiacono G, Polosa R. Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur Respir J. 2011;38:1005–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Caponnetto P, Polosa R, Russo C, Leotta C, Campagna D. Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep. 2011;5:585.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health. 2011;11:786.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.••
    Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R: EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2014; 8. doi: 10.1371/journal.pone.0066317. This article is the first published randomized trial of an e-cigarette Google Scholar
  49. 49.••
    Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382:1629–37. This article is the most widely cited randomized trial of an e-cigarette for smoking cessation.PubMedCrossRefGoogle Scholar
  50. 50.
    Dockrell M, Morison R, Bauld L, McNeill A. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob Res. 2013;15:1737–44. doi: 10.1093/ntr/ntt057.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.••
    Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction. 2014. doi: 10.1111/add.12623. This article provides first-time population data from the UK, indicating that e-cigarettes have cessation potential.PubMedCentralGoogle Scholar
  52. 52.••
    West R. Smoking in England. http://www.smokinginengland.info/latest-statistics/. Accessed 25 July 2014. Fascinating new data from the UK on the possible role of e-cigarettes in reducing population smoking prevalence.
  53. 53.
    Zeller M, Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18:324–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Foulds J, Veldheer S, Berg A. Electronic cigarettes (e-cigs): views of aficionados and clinical/public health perspectives. Int J Clin Pract. 2011;65:1037–42.PubMedCrossRefGoogle Scholar
  55. 55.
    Kralikova E, Novak J, West O, Kmetova A, Hajek P. Do e-cigarettes have the potential to compete with conventional cigarettes? A survey of conventional cigarette smokers’ experiences with e-cigarettes. Chest. 2013;18:12–2842.Google Scholar
  56. 56.
    Lechner WV, Tackett AP, Grant DM, Tahirkheli NN, Driskill LM, Wagener TL. Effects of duration of electronic cigarette use. Nicotine Tob Res. 2014. doi: 10.1093/ntr/ntu061.PubMedGoogle Scholar
  57. 57.
    US Department of Health Education and Welfare: Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. In Public Health Service Publication Washington: US Department of Health, Education and Welfare, Public Health Service. 1964.Google Scholar
  58. 58.
    Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328:1519.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Benowitz NL, Hansson A, Jacob P. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension. 2002;39:1107–12.PubMedCrossRefGoogle Scholar
  60. 60.
    Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol. 2001;37:1297–302.PubMedCrossRefGoogle Scholar
  61. 61.
    Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–31.PubMedCrossRefGoogle Scholar
  63. 63.•
    Cheng T. Chemical evaluation of electronic cigarettes. Tob Control. 2014;23:2013–051482. This article provides an account of findings from a systematic literature review of the chemical constituents of e-cigarettes.CrossRefGoogle Scholar
  64. 64.
    Pellegrino RM, Tinghino B, Mangiaracina G, Marani A, Vitali M, Protano C, et al. Electronic cigarettes: an evaluation of exposure to chemicals and fine particulate matter (PM). Ann Ig. 2012;24:279–88.PubMedGoogle Scholar
  65. 65.•
    Callahan-Lyon P. Electronic cigarettes: human health effects. Tob Control. 2014;23:ii36–40. This article provides an account of findings from a systematic literature review of the health effects of e-cigarettes.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Bjartveit K, Tverdal A. Health consequences of smoking 1–4 cigarettes per day. Tob Control. 2005;14:315–20.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Bullen C, Whittaker R, McRobbie H, Fagerstrom K. A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. Prev Cardiol. 2007;10:5–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.National Institute for Health Innovation, School of Population HealthThe University of AucklandAucklandNew Zealand

Personalised recommendations